2-Chlorodeoxyadenosine (2-CdA) is a purine analog with cytotoxic activity on both resting and cycling lymphocytes which has been used as salvage therapy in advanced/resistant chronic lymphoproliferative disorders. In our study 39 patients (19 B-CLL, 5 B-PLL, 9 low-grade B-NHL, 5 CTCL and 1 high-grade T-NHL) who relapsed or became resistant after 1-4 chemotherapy regimens were treated with 2-CdA 6 mg/m2 per day by 2 h infusion for 5 d every 28 d. The overall clinical response rate, including complete remission (CR) and partial remission (PR), was 66\%. Two of 19 (10\%) B-CLL patients achieved a CR lasting 9 months, while 11/19 B-CLL (58\%) and 4/5 B-PLL (3 B-PLL/B-CLL and 1 B-PLL) (80\%) achieved a PR. Interestingly, 5 of 6 patients who had been previously treated with fludarabine obtained a clinical response (2 CR and 3 PR). One of 9 (11\%) low-grade B-NHL patients achieved a CR and relapsed after 26 months, and 5/9 (55\%) achieved a PR. One of 5 (20\%) CTCL achieved a CR lasting 32 months, while 2/5 (40\%) achieved a PR. The overall mean duration of PR was 7.4 months and no differences were observed among different groups of patients. Toxicity was acceptable, as only a transient severe hematological impairment was observed in 20\% of the patients while nonhematological toxicity was not documented. Two patients died because of bacterial pneumonia, 1 of meningitis due to Listeria and 9 from progression of the disease. In conclusion, treatment with 2-CdA in heavily pretreated patients with chronic lymphoproliferative disorders is well tolerated and obtains high response rates, even in patients relapsed after treatment with fludarabine.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.|
|Citazione:||D., R., Lauria, F., P. L., Z., D., R., M. A., V., P., G., et al. (1997). 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. EUROPEAN JOURNAL OF HAEMATOLOGY, 58, 46-50.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto:
|1997 Rondelli Eur J Haem 2CdA j.1600-0609.1997.tb01409.x.pdf||Post-print||NON PUBBLICO - Accesso privato/ristretto||Administrator Richiedi una copia|